HeartLung Corporation's AI-CVD receives FDA clearance for opportunistic multi-condition screening on routine chest CT scans.
Key Details
- 1FDA grants 510(k) clearance to HeartLung Corporation's AI-CVD algorithm.
- 2AI-CVD performs 11 opportunistic screening assessments on chest CT scans.
- 3Assesses for findings like coronary calcium, valve and wall calcium, volumetry, lung and liver attenuation, bone mineral density, and more.
- 4Alerts doctors to incidental findings that may indicate risk for conditions such as heart disease, stroke, osteoporosis, diabetes, and liver steatosis.
- 5Can be used for both new and prior CT scans, supporting broader preventive care.
- 6Platform potentially applicable to nearly 40 million CT scans per year in the U.S.
Why It Matters
This clearance introduces the most comprehensive FDA-cleared AI platform for opportunistic screening on CT, enabling earlier identification of at-risk patients and broadening the utility of routine imaging for preventive care. Radiology practices may see an expanded role in population health management through automated, multi-disease detection.
Source
Cardiovascular Business
Related News
•Radiology Business
Framework Assesses Real-World Financial Impact of Radiology AI Adoption
A new analysis presents a financial calculator for objectively assessing the return on investment (ROI) of implementing radiology AI solutions.
•Radiology Business
Study Finds Disparities in Access to Stroke Imaging AI Tools
Research shows access to AI stroke detection tools is concentrated in resource-rich hospitals despite Medicare incentives.
•Cardiovascular Business
AI Is Quietly Embedded in Cardiac Imaging Workflows
AI is now seamlessly integrated into cardiac imaging, often unnoticed by clinicians.